To vaccinate or not to vaccinate—this is the question: Are COVID‑19 vaccines safe for children?

Release date:

2024-04-02

Author:

Source:


Abstract

Recently, COVID‑19 vaccination for children aged 3 to 11 has been gradually rolled out across the country. With the rollout comes a wave of questions from parents. More than concerns about vaccine efficacy, parents are primarily worried about whether the vaccines are safe for their children. In fact, there is no need for concern: the COVID‑19 vaccines currently administered to children in China have been proven safe. According to national guidelines, all COVID‑19 vaccines authorized for use in this age group are inactivated vaccines; other types of vaccines have not yet been approved for children in this age range. Inactivated vaccines have a history spanning more than a century.

Recently, COVID-19 vaccination for children aged 3 to 11 has been gradually rolled out across the country. With the official notice issued, parents have begun raising a variety of questions. Compared with the vaccine’s efficacy, parents are more concerned about… “Are vaccines safe for children?” The problem.

In fact, parents need not worry at all; the COVID-19 vaccines currently administered to children in China are… Security is still guaranteed. Because, in accordance with national requirements, the COVID-19 vaccines currently administered to children aged 3 to 11 are all “Inactivated vaccine” Vaccines produced by other manufacturing processes have not yet been approved for use in children of this age group.

Inactivated vaccine Over 100 years of traditional craftsmanship

Inactivated COVID‑19 vaccines, as the name suggests, are vaccines made using the “dead” remains of the SARS‑CoV‑2 virus as the antigen. These “dead” pathogens, their It has already completely lost its transmissibility and pathogenicity. So what is there to be afraid of?

The virus inactivation process was developed over a century ago and has been continuously refined and upgraded ever since, having reached a stage of mature development. Relatively mature vaccine manufacturing processes

Common inactivated vaccines for children, such as the inactivated poliovirus vaccine, Japanese encephalitis inactivated vaccine, hepatitis A inactivated vaccine, influenza inactivated vaccine, rabies vaccine, and the EV71 vaccine for hand, foot, and mouth disease, all belong to the category of inactivated‑vaccine technologies. And the inactivated COVID‑19 vaccine is just like these other inactivated vaccines, Apart from having a different antigenic component, There is no essential difference. Therefore, parents need not harbor excessive concerns about inactivated vaccines due to the global disruptions caused by the COVID‑19 pandemic; getting vaccinated as soon as possible is the best way to provide your child with more comprehensive protection.

According to current clinical trial data, the most common adverse reactions in children and adolescents aged 3–17 years following vaccination are pain and redness at the injection site; a small number of individuals may also experience fever, fatigue, nausea, headache, and muscle aches. These are all typical “adverse reactions” that resolve on their own and do not have any “pathological” effects on the child. At present, the contraindications and safety profile of COVID-19 vaccination in children are comparable to those in adults, so no special precautions are required. However, if your child has “special circumstances” affecting the development of various functions, you should take note: in the following 26 situations, COVID‑19 vaccination is either not recommended or should be postponed.

 

Recommended Reading


Batch Release Status of the Company’s Products in 2026


The company's product 2026 annual batch issuance situation is as follows:

2026-07-23

Good News | Another Star Award! Minhai Biotechnology has once again been recognized as a “Five-Star Green Credit Enterprise” in Daxing District.


Recently, the Daxing District Bureau of Ecology and Environment completed the fifth round of corporate green credit rating for 2025 and officially released the “2025 Daxing District Green Credit Enterprise Directory.” Thanks to its robust environmental management system, consistent compliance performance, and outstanding achievements in energy conservation and carbon reduction, Minhai Biotechnology has once again been awarded the region’s highest “Five-Star Green Credit Enterprise” rating. The Daxing District’s corporate green credit assessment covers five major categories—environmental compliance, pollution control and emission reduction, low‑carbon circular economy, scientific management, and social contribution—comprising a total of 30 sub‑indicators. With stringent standards and comprehensive evaluation, the program employs dynamic review and a veto‑based mechanism, with the Five‑Star rating representing the highest level of ecological credit in the district.

2026-07-15

Good News | The Party Branch of Minhai Biotechnology has been awarded the “Two Excellences and One Pioneer” honor in Beijing’s emerging sectors, as well as a park‑level commendation.


Recently, Beijing held a grand commendation conference for the “Two Excellences and One Pioneer” initiative in emerging sectors. The “Two New” Working Committee of the CPC Beijing Municipal Committee recognized outstanding Communist Party members, exemplary Party affairs workers, and advanced primary-level Party organizations across the city’s emerging fields. The Party branch of Beijing Minhai Biotechnology Co., Ltd. was honored as an advanced primary-level Party organization in Beijing’s emerging sectors. Wu Chengyu, the branch secretary, attended the ceremony in person to receive the award. At the event, the Party flag flew proudly amid a solemn atmosphere, and the awardees, adorned with honor ribbons and holding certificates and medals, jointly witnessed this prestigious municipal recognition. This designation as an advanced primary-level Party organization at the municipal level represents the “Two New” Working Committee of the Municipal Party Committee’s high appraisal of the Minhai Biotechnology Party branch.

2026-07-09